AZN — AstraZeneca Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapHigh Flyer

Annual cashflow statement for AstraZeneca, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	1,548	3,916	-265	2,501	6,899
Depreciation
Non-Cash Items	511	-60	127	460	657
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-2,852	-2,206	-429	1,367	-2,598
Change in Accounts Receivable
Change in Inventories
Change in Payable / Accrued Expenses
Other Operating Cash Flow
Cash from Operating Activities	2,969	4,799	5,963	9,808	10,345
Capital Expenditures	-2,460	-2,606	-2,200	-2,571	-3,778
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	1,803	2,321	-8,858	-389	-286
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	-657	-285	-11,058	-2,960	-4,064
Financing Cash Flow Items	4	-101	-178	-1,047	-886
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-1,765	-2,203	3,649	-6,823	-6,567
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	552	2,323	-1,508	-55	-346